维拉斯特姆肿瘤

Though Verastem Inc appears cheap due to heavy downward pressure in the past year, we have capped its rating at 3 stars to factor in the possibility that it represents a value trap. The stock currently trades at a 33% discount to our quantitative fair value estimate of $12.33 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The firm's balance sheet bolsters our quantitative valuation. Low leverage mitigates financial risk, potentially boosting a firm's value. For example, the firm's current ratio of 2.3 sits in the top 40% compared with global peers. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which contributes to our view that shares are undervalued.

Alternatively, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of -25.1%, a core component of profitability, sits in the bottom 10% globally. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.